Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Autoimmunity, Alopecia universalis, Alopecia totalis, and Patchy alopecia and 2 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 4 | Alopecia universalis, Alopecia totalis, Patchy alopecia |
Blood and immune system |
Biomarker and diagnostic research for alopecia areata 1 has been reported in the published literature.
7 clinical trials registered, 4 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 2 PHASE4, 2 PHASE3, 1 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07406204](https://clinicaltrials.gov/study/NCT07406204) |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 7:45 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
1
Autoimmunity |
Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)
PHASE4 |
Hayat Abad Medical Complex, Peshawar |
NOT_YET_RECRUITING |
[NCT00069589](https://clinicaltrials.gov/study/NCT00069589) | Alopecia Areata Registry | — | M.D. Anderson Cancer Center | ACTIVE_NOT_RECRUITING |
[NCT06747611](https://clinicaltrials.gov/study/NCT06747611) | Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata | PHASE2 | University of Minnesota | RECRUITING |
[NCT06283316](https://clinicaltrials.gov/study/NCT06283316) | Systemic Treatments for Alopecia Areata Registry | — | Erasmus Medical Center | RECRUITING |
[NCT04006457](https://clinicaltrials.gov/study/NCT04006457) | Long-Term PF-06651600 for the Treatment of Alopecia Areata | PHASE3 | Pfizer | UNKNOWN |
98 publications have been identified in PubMed for alopecia areata 1. Research spans Case Report / Case Series (36%), Clinical Trial Publication (32%), and Review / Meta-Analysis (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 35 | 36% |
Clinical study results | 31 | 32% |
Research summaries | 9 | 9% |
Disease patterns and progression | 9 | 9% |
Other research | 5 | 5% |
Laboratory research | 5 | 5% |
Testing and diagnosis research | 3 | 3% |
New treatment approaches | 1 | 1% |
Joshi R (2026). [PMID: 40924677](https://pubmed.ncbi.nlm.nih.gov/40924677/). *Indian dermatology online journal*. [Case Report / Case Series]
Alzahrani D (2026). [PMID: 41869422](https://pubmed.ncbi.nlm.nih.gov/41869422/). *Clin Cosmet Investig Dermatol*. [Case Report / Case Series]
Pohoreski KT (2026). [PMID: 42110117](https://pubmed.ncbi.nlm.nih.gov/42110117/). *JPGN Rep*. [Case Report / Case Series]
Fan A (2026). [PMID: 41656280](https://pubmed.ncbi.nlm.nih.gov/41656280/). *Stem cell research & therapy*. [Clinical Trial Publication]
Gowda SK (2026). [PMID: 41108789](https://pubmed.ncbi.nlm.nih.gov/41108789/). *The International journal of risk & safety in medicine*. [Epidemiology / Natural History]
Blume-Peytavi U (2026). [PMID: 41855094](https://pubmed.ncbi.nlm.nih.gov/41855094/). *J Dtsch Dermatol Ges*. [Review / Meta-Analysis]
Trost SU (2026). [PMID: 42039112](https://pubmed.ncbi.nlm.nih.gov/42039112/). *JCEM Case Rep*. [Case Report / Case Series]
Parikh AK (2026). [PMID: 42246366](https://pubmed.ncbi.nlm.nih.gov/42246366/). *Dermatol Online J*. [Other]
Velaoras AT (2026). [PMID: 41779754](https://pubmed.ncbi.nlm.nih.gov/41779754/). *Journal of drugs in dermatology : JDD*. [Clinical Trial Publication]
Matteini E (2026). [PMID: 41744512](https://pubmed.ncbi.nlm.nih.gov/41744512/). *Clinics and practice*. [Clinical Trial Publication]
AI-curated news mentioning alopecia areata 1
Updated Jul 25, 2026
A 4.5-year retrospective cohort study evaluates the safety of JAK inhibitors in patients with atopic dermatitis and alopecia areata. The findings contribute to understanding the long-term effects of these treatments in real-world settings.
PRAC has agreed on new safety information regarding desogestrel- and etonogestrel-containing contraceptives and Litfulo for alopecia areata. This meeting highlights ongoing pharmacovigilance efforts but does not indicate any new approvals or significant changes.
MHRA has approved deuruxolitinib for adults suffering from severe alopecia areata, a condition characterized by extensive hair loss. This approval marks a significant advancement in treatment options for patients affected by this autoimmune disorder.